The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

April 13, 2020 • By Luis A. Marcos, MD, MPH, Saika Sharmeen, DO, Jaime Gonzalez, MD, Qingping Yao, MD, PhD, Bettina Fries, MD, & Jack Fuhrer, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

These cases present some intriguing considerations regarding the immunological underpinning of COVID.

You Might Also Like
  • The COVID-19 Infection Inflammation Equation
  • Don’t Forget the Host: COVID-19 Cytokine Storm
  • Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients
Explore This Issue
May 2020

The clinical course of COVID-19 varies from mild to critical, possibly progressing to death. Cytokine storm, macrophage activation syndrome (MAS) and secondary hemophagocytic lymphohistiocytosis (sHLH) are disease processes triggered by infections, autoimmune diseases, drugs or malignancy. Clinically, cytokine storm presents with a syndrome of excessive immune activation that causes fever, pancytopenia, hyperferritinemia, splenomegaly, hepatitis, encephalopathy and coagulopathy. The etiology is thought to be caused by excessive activation and proliferation of T lymphocytes and macrophages with massive hypersecretion of proinflammatory cytokines, including interleukin 1 beta (IL-1β), IL-6, interferon-γ (IFN-γ), and tumor necrosis factor α (TNFα).3,4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Huang et al. described a cytokine profile similar to that in sHLH, which is associated with COVID-19 disease severity. It is characterized by increased IL-2, IL-7, granulocyte-colony stimulating factor, IFN-γ inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α and TNFα. It is well known that IL-6 and IL-1β blockade has been successfully used in treating MAS secondary to systemic juvenile idiopathic arthritis (sJIA).5,6 That success has led to clinical trials where more than one-third of patients achieved clinical remission.7,8 Additionally, the IL-1 receptor inhibitor, anakinra, has been associated with improved survival in sepsis with MAS-like features.9 Similarly, the IL-6 antagonist, tocilizumab, could suppress the cytokine storm, as suggested by early promising results in a small cohort of COVID-19 patients.10 Therefore, it is worthwhile exploring whether blocking other cytokines involved in MAS or sHLH may be beneficial in cases of cytokine storm from COVID-19 infection.

TNFα may play a key role in the cytokine storm. TNFα is a 26 kd homotrimeric transmembrane protein expressed on the surface of macrophages, T lymphocytes, natural killer cells, smooth muscle cells and fibroblasts. TNFα, along with IFN-γ, plays a significant role in the immune response against viral infections. TNFα and IFN-γ exhibit a cross-talk at the level of TNF receptor 1 (TNFR1) to induce activation of macrophages. IFN-γ signaling causes nuclear localization of STAT1α that precludes it from being recruited at TNFR1, leading to an enhanced TNFα-induced NFκB activation.11-13  

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Blocking IFN-γ with emapalumab has been described in successfully treating secondary HLH due to multiple viral infections.14 Emapalumab is a human monoclonal antibody to IFN-γ that acts to block its binding to cell surface receptors and activation of inflammatory signals. Emapalumab is used to treat severe HLH in which serum IFN-γ levels are elevated.15,16

Similarly, TNFα inhibition may theoretically increase the risk of viral infections, but could potentially be beneficial in cases of cytokine storm.17 From the literature on the 2003 SARS-CoV infection, it is suggested the viral infection is associated with decreased angiotensin-converting enzyme 2 (ACE2) expression, leading to an increased activity of the renin-angiotensin system responsible for lung injury.18

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions Tagged With: COVID-19Issue: May 2020

You Might Also Like:
  • The COVID-19 Infection Inflammation Equation
  • Don’t Forget the Host: COVID-19 Cytokine Storm
  • Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients
  • Unprecedented Cluster of Hyperinflammatory Shock in Kids in U.K., possibly Linked to COVID-19

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)